Clinical Trials

Bright Mind Shares Surge 91% After Reporting Positive EEG Clinical Results Of Next-Gen Compound
Atai Update: Ketamine Trials Are Ongoing, Company Cuts 30% Workforce
Numinus Debuts 3rd Research Site In US, Touts Faster Services & More Participants
Atai Update: Ketamine Trials Are Ongoing, Company Cuts 30% Workforce
Numinus Debuts 3rd Research Site In US, Touts Faster Services & More Participants
These Are The 11 Biggest Psychedelics News And Trends You May Have Missed Last Year
Psychedelic Mushrooms Soon To Be Commercially Produced And Sold In Canada

Clinical Trials Recent News

Psychedelics And Treatment-Resistant Depression: COMPASS Pathways Replies To Comments
(Part four of a four-part series) See previous stories: 
Reunion Neuroscience Presents Q2 2023 Financial Results & Pipeline Update
Psychedelics biopharma company Reunion Neuroscience Inc. (NASDAQ: REUN) reported its business update and fiscal results for the second quarter ended September 30, 2022.
MindMed's Q3 2022 Financials & Business, Setting The Stage For Phase 3 Trials
Clinical-stage biotech company Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) reported its financial results and updated on its programs pipeline of the third quarter ended September 30, 2022.
Atai Life Sciences' Q3 2022 Financials & Business Update, 'Strong Capability To Execute'
Clinical-stage psychedelics company atai Life Sciences N.V. (NASDAQ: ATAI) reported its financial results for the quarter ended September 30, 2022 and shared business developments.
Michigan Report: $20M In Cannabis Cash To Research PTSD Among Veterans And Using Weed Does Not Disqualify Unemployment Eligibility
The state of Michigan is funding two major medical cannabis research projects to the tune of $20 million with tax revenue from the state’s recreational marijuana program, announced Michigan’s Marijuana Regulatory Agency (MRA).
The Week Ahead In Biotech (Aug. 8-14): Jazz Pharma FDA Decision, Earnings Deluge and IPOs In The Spotlight
Biopharma stocks ended higher for the week ending Aug. 6, as the sector latched on to the optimism that was evident in the broader markets. Earnings continued to flow in, triggering stock-specific moves, while clinical readouts also moved stocks during the week.
Why Novavax Shares Spiked 32% Today
Novavax, Inc (NASDAQ: NVAX) shares spiked nearly 32% in the after-hours and regular session on Thursday.
Why ChromaDex Shares Spiked 111% Today
Chromadex Corp (NASDAQ: CDXC) shares jumped 111% in the regular and after-hours sessions today. What Happened: The price movement on Thursday was accompanied by intense trading with volumes of 116.67 million. The average volume for ChromaDex shares is 523,511.
China's Sinopharm COVID-19 Vaccine Shows 79.34% Efficacy
China's Sinopharm Group (OTC: SHTDY) said Wednesday its COVID-19 vaccine candidate BBIBP-CorV — developed in partnership with Beijing Biological Products Institute Co.
AstraZeneca COVID-19 Vaccine Shows Up To 90% Efficacy In Advanced Trials
AstraZeneca Plc (NYSE: AZN) and Oxford University’s COVID-19 vaccine prevented 70% of the inoculated trial participants from developing COVID-19, early analysis of trial data indicates, Bloomberg
Johnson & Johnson Begins Two-Dose Phase 3 Trial Of COVID-19 Vaccine
Johnson & Johnson (NYSE: JNJ) has started the two-dose Phase 3 trial of its experimental COVID-19 vaccine, dubbed "ENSEMBLE 2," the pharmaceutical company an
Sinovac COVID-19 Vaccine Trial Halted In Brazil Over Adverse Event
Brazilian health regulator has decided to halt clinical trials of a frontrunning Chinese vaccine following a “severe adverse event” observed in a participant, Bloomberg reported Monday.
GW Pharmaceuticals Revenue Hits $137M, Tests Another Cannabis Plant-Based Drug
Biopharmaceutical company GW Pharmaceuticals plc (NASDAQ: GWPH) revealed Tuesday that its revenue for the third quarter hit $137.1 million, up by 51% year-over-year.
AstraZeneca Could Resume US COVID-19 Vaccine Trial This Week As FDA Review Complete: Report
The U.S.
Johnson & Johnson COVID-19 Vaccine Trial Paused Over Participant Developing Unexplained Illness
Johnson & Johnson’s (NYSE: JNJ) COVID-19 vaccine trial has been paused over a participant developing an unexplained illness, Stat reported late Monday.
Regeneron CEO Says More Testing Needed For Antibody Cocktail After Trump Touted It As COVID-19 'Cure'
Regeneron Pharmaceuticals Inc (NASDAQ: REGN) CEO Leonard Schleifer in a televised interview suggested that more clinical testing was needed to measure the company's antibody cocktail's effecti
Novavax Shares Surge 7% As It Begins Late-Stage COVID-19 Vaccine Trials
Novavax, Inc (NASDAQ: NVAX) said Thursday it was launching a large-scale diverse Phase 3 study of its COVID-19 vaccine in the United Kingdom — causing a more than 7% spike in the company’s shares after the closing bell.
Sinovac Plans To Expand COVID-19 Vaccine Trials To Children And Adolescents
Sinovac Biotech has plans to expand the clinical trial of its COVID-19 vaccine trial to children and adolescents later this month.
AstraZeneca Gets India Go-Ahead To Resume COVID-19 Vaccine Trials, US Nod Awaited
AstraZeneca plc (NYSE: AZN) COVID-19 vaccine clinical trial is set to resume in India after local partner Serum Institute of India received the go-ahead from Indian regulators, Reuters reported Wednesday.
Pfizer Says COVID-19 Vaccine Only Showed Moderate Side-Effects In Preliminary Late-Stage Trials
Pfizer Inc (NYSE: PFE) on Tuesday said only mild-to-moderate side effects were observed in volunteers administered with its COVID-19 vaccine in late-stage human trials.
Pfizer Seeks FDA Nod To Expand Late-Stage COVID-19 Vaccine Trial
Pfizer Inc (NYSE: PFE) and its German partner BioNTech SE (NASDAQ: BNTX) said Saturday they are seeking the United States Food and Drug Administration approval to expand the late-stage clinical trial of their COVID-19 vacc
AstraZeneca COVID-19 Vaccine Trial Halt A 'Wake-Up Call,' WHO Says
AstraZeneca Plc’s (NYSE: AZN) COVID-19 vaccine trial halt is an indicator that vaccine development is “not always a fast and a straight road,” according to the World Health Organization Chief Scientist Dr. Soumya Swaminathan.
AstraZeneca COVID-19 Vaccine Trial Volunteer Showed Symptoms Of Rare Neurological Disorder
AstraZeneca Plc (NYSE: AZN) CEO Pascal Soriot said during a conference call with investors Wednesday that a person experiencing symptoms related to a rare neurological disorder caused its global COVID-19 vaccine trials to pause, Stat